MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why OM Stock dropped -3.46% Today — RQD Quant Desk Flash
$4.19 -3.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.16
Outset Medical Inc. (OM) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $78.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.16 (-0.81%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY OM SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)
FRED Regime × Technicals: 13% of 52W Range • RSI-14 at 51.8 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 39.1% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.05-2.7% Next Q
27
Q2 (-2Q)Grade E$3.94+4.1% Next Q
30
Q3 (-1Q)Grade E$4.10+2.2% Next Q
32
CurrentGrade D-$4.19-8.5% Hist 90D α
35
Trajectory: E (27) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a OM Turnaround Squeeze
While OM currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.73) and Max Pain ($4.40) forces dealer call-delta covering toward $13.95.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OM Stock dropped -3.46% Today — RQD Quant Desk Flash
Outset Medical Inc. (OM) dropped -3.46% to $4.19, trading at 13% of its 52-week range ($2.84 – $13.29). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 13% of its 52-week range ($2.84 – $13.29) with RSI-14 at 51.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.19 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 39.1% gross margin and $0 annual free cash flow.
Live OM Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 5h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 6h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 7h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 8h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OM)
- ✓Walkthrough of OM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.87%▼ DESCENDING CHANNEL
2026-10-30O $4.02H $4.19L $3.90C $4.19VOL 81.5K
RES: $4.72SUP: $2.28SMA50: $3.73SMA200: $4.15
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +5.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on OM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OM)
Health Care Rank #823 of 1016
⚔️ HYPR vs OM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OM vs. HYPR, ECOR, STXS, NRXS)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Outset Medical Inc. (OM) ranks #823 by composite RQD confidence (35/100, grade D-) and #692 by equity capitalization ($78.8M). Within this direct 5-issuer industry benchmark cohort, OM leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with OM at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OM
ACTIVE
Outset Medical Inc. | D- | 35/100 | — | 39.1% | -28.0% | -3.46% | $78.8M | Benchmark Subject |
| HYPR Hyperfine Inc. (Class A) | D | 45/100 | — | 49.8% | -35.0% | -5.23% | $78.9M | /hypr-vs-om → |
| ECOR electroCore Inc. | D- | 38/100 | — | 86.8% | -35.0% | -3.68% | $73.1M | /ecor-vs-om → |
| STXS Stereotaxis Inc. | E | 30/100 | — | 52.7% | -35.0% | -6.21% | $91.2M | /stxs-vs-om → |
| NRXS Neuraxis Inc. | E | 32/100 | — | 84.2% | -35.0% | -0.26% | $94.8M | /nrxs-vs-om → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001484612In its most recent audited fiscal period (FY2025, filed 2025-12-31), Outset Medical Inc. (OM) reported GAAP revenue of $119.5M (+5.1% vs. FY2024 revenue of $113.7M , and -8.4% cumulative change since FY2023) , GAAP net income of -$81.7M, operating cash flow of -$46.3M, and free cash flow of -$47.1M (+59.8% YoY). On the balance sheet, OM closed FY2025 with $264.5M in total assets against $96.2M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $119.5M | -$81.7M | -$46.3M | -$47.1M | $264.5M | $96.2M |
| FY2024 (FY) | 2024-12-31 | $113.7M | -$128.0M | -$116.3M | -$117.2M | $275.8M | $197.4M |
| FY2023 (FY) | 2023-12-31 | $130.4M | -$172.8M | -$131.4M | -$131.4M | — | — |
3. OM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Outset Medical Inc. (NASDAQ: OM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $4.19 (-3.46% 1D, market cap $78.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, OM ranks #823 in composite RQD confidence.
How does OM compare to HYPR and ECOR in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), OM carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 39.1%, and ROIC of -28.0%. By comparison, HYPR (Hyperfine Inc. (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $78.9M) and ECOR (electroCore Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $73.1M). Among the 5-stock peer group, OM leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OM?
Per OM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001484612), Outset Medical Inc. generated $119.5M in revenue (+5.1% YoY), -$81.7M in net income, and -$47.1M in free cash flow against $264.5M in total assets and $96.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OM trading relative to its 50-day, 200-day, and 52-week technical levels?
OM last traded at $4.19 (-3.46% on volume of 77,803 shares), positioning the stock +12.33% above its 50-day simple moving average ($3.73) and +0.96% above its 200-day simple moving average ($4.15). Across its 52-week range of $2.84 to $13.29, OM sits at the 12.9% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.67 to $4.71).
OM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is OM stock moving today?
Why OM Stock dropped -3.46% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.